These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6364892)

  • 21. Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease: a randomized, double-blind, placebo-controlled trial.
    Arosio E; De Marchi S; Zannoni M; Prior M; Lechi A
    Mayo Clin Proc; 2002 Aug; 77(8):754-9. PubMed ID: 12173710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The anti-hypoxaemic effect of cyclandelate in man measured in human volunteers using computer-assisted oculodynamic methodology.
    Schaffler K
    Br J Clin Pract Suppl; 1984; 34():51-7. PubMed ID: 6430324
    [No Abstract]   [Full Text] [Related]  

  • 23. Determination of plasma concentrations of cyclandelate and mandelic acid in patients with generalized atherosclerotic vasculopathy treated with oral cyclandelate.
    Forconi S; Cappelli R; Guerrini M; Volpi L; Frigerio C; Di Perri T
    J Int Med Res; 1990; 18(4):266-72. PubMed ID: 2227073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclandelate in the management of tinnitus: a randomized, placebo-controlled study.
    Hester TO; Theilman G; Green W; Jones RO
    Otolaryngol Head Neck Surg; 1998 Mar; 118(3 Pt 1):329-32. PubMed ID: 9527112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclandelate in the treatment of vertigo of circulatory origin. A study in general practice.
    de Halleux F
    Drugs; 1987; 33 Suppl 2():114-9. PubMed ID: 3622305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical effects of Cyclospasmol in patients affected by chronic cerebrovascular disorders.
    Albizzati MG; Bassi S; Sbacchi M; Frattola L
    Br J Clin Pract Suppl; 1984; 34():69-73. PubMed ID: 6430327
    [No Abstract]   [Full Text] [Related]  

  • 27. [Controlled clinical study of Novodil in the treatment of senile macular lesions].
    Delafoulhouje C; Dalens H; Solé P
    Bull Soc Ophtalmol Fr; 1985 Oct; 85(10):1065-7. PubMed ID: 3915881
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of Cyclospasmol upon sensory parameters in patients recovering from cerebrovascular accidents.
    Sourander L; Blakemore CB
    Angiology; 1978 Feb; 29(2):133-8. PubMed ID: 347985
    [No Abstract]   [Full Text] [Related]  

  • 29. Cyclandelate in the treatment of multi-infarct dementia. Interim findings from a multicentre study in general practice.
    Blakemore CB
    Drugs; 1987; 33 Suppl 2():110-3. PubMed ID: 3622304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and microcirculatory effects of transcutaneous CO2 therapy in intermittent claudication. Randomized double-blind clinical trial with a parallel design.
    Fabry R; Monnet P; Schmidt J; Lusson JR; Carpentier PH; Baguet JC; Dubray C
    Vasa; 2009 Aug; 38(3):213-24. PubMed ID: 19736632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perceived efficacy of cyclandelate in the treatment of cochleovestibular and retinal disturbances related to cerebrovascular insufficiency. A study in general practice comprising 2772 patients.
    Memin Y
    Drugs; 1987; 33 Suppl 2():120-4. PubMed ID: 3497796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of atherosclerosis in the rabbit by cyclandelate.
    Middleton A; Edwards E; White DA; Middleton B
    Br J Clin Pract Suppl; 1984; 34():39-42. PubMed ID: 6430322
    [No Abstract]   [Full Text] [Related]  

  • 33. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
    Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
    Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of the assessment of primary and secondary endpoints in claudication and critical leg ischemia trials.
    Hiatt WR; Cox L; Greenwalt M; Griffin A; Schechter C
    Vasc Med; 2005 Aug; 10(3):207-13. PubMed ID: 16235774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrinolytic activity of oral cyclandelate in patients with generalized atherosclerotic vasculopathy: a double-blind study.
    Forconi S; Cappelli R; Guerrini M; Frigerio C; Messa GL; Furesi L
    J Int Med Res; 1990; 18(4):257-65. PubMed ID: 2121564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-surgical management of peripheral vascular disease.
    Br Med J; 1980 Nov; 281(6250):1278-9. PubMed ID: 7427664
    [No Abstract]   [Full Text] [Related]  

  • 37. Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study.
    Gerber WD; Schellenberg R; Thom M; Haufe C; Bölsche F; Wedekind W; Niederberger U; Soyka D
    Funct Neurol; 1995; 10(1):27-35. PubMed ID: 7649498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and Causes of Normal Exercise Oximetry in the Calf in Patients with Peripheral Artery Disease and Limiting Calf Claudication.
    Signolet I; Henni S; Colas-Ribas C; Feuilloy M; Picquet J; Abraham P
    Eur J Vasc Endovasc Surg; 2016 Apr; 51(4):572-8. PubMed ID: 26905471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical efficacy of Cyclospasmol: a review of the literature.
    Blakemore CB
    Br J Clin Pract Suppl; 1984; 34():3-9. PubMed ID: 6430319
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication.
    de Albuquerque RM; Virgini-Magalhães CE; Lencastre Sicuro F; Bottino DA; Bouskela E
    Angiology; 2008; 59(5):549-58. PubMed ID: 18388031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.